Citigroup started coverage on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a report released on Monday, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $21.00 price target on the stock.
Other equities analysts have also issued reports about the stock. Evercore ISI assumed coverage on shares of Mirum Pharmaceuticals in a research report on Monday. They set an outperform rating and a $25.00 target price on the stock. Guggenheim assumed coverage on shares of Mirum Pharmaceuticals in a research report on Monday. They set a buy rating and a $18.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, Mirum Pharmaceuticals currently has an average rating of Buy and a consensus price target of $25.00.
Mirum Pharmaceuticals stock opened at $13.45 on Monday. Mirum Pharmaceuticals has a 1-year low of $12.05 and a 1-year high of $15.50.
In related news, insider James E. Flynn bought 332,000 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, July 22nd. The shares were acquired at an average cost of $15.00 per share, with a total value of $4,980,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Patrick J. Heron bought 450,000 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, July 22nd. The shares were bought at an average cost of $15.00 per share, for a total transaction of $6,750,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 1,357,000 shares of company stock worth $20,355,000.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).
Recommended Story: Swap
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.